Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy
Status:
Unknown status
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
to show that
1. patients improve and stabilize after 12 -24 week treatment with rivastigmine in memory
function
2. use of rivastigmine has a positive effect on apathy in PSP patients
3. therapy with rivastigmine has a no positive benefit on speech and overall results of the
MMST
4. changes in motor activity are associated with changes in language and overall results of
the in MMST